GrowBLOX Sciences Chief Executive Officer Craig Ellins shared, “First joining us as a consultant, the performance of John Poss and his impact on our Company, made the hiring of him as a full-time key executive an obvious choice. This choice supports our transition from the engineering intensive development stage to the day-to-day operations of producing an excellent product, branding it appropriately, and maximizing our revenue. We feel that John will be instrumental in helping us to achieve that transition smoothly and expeditiously.”

John Poss possesses tremendous talents. He has a history as a senior executive with an aptitude for solving complex problems and improving performance in technology, logistics, business systems, and finance. His experience includes CFO, CEO, COO, and CTO of both public and private companies with sales ranging from $10 million to $450 million as well as over 15 years of consulting experience. Mr. Poss also has extensive M&A experience, both buy and sell side, including private equity. His success has been demonstrated across multiple industries, including telecommunications, transportation/logistics, manufacturing, finance/mortgage, construction, mining, oil, gas, and public accounting/consulting. Additionally, he is a proven innovator with two issued Patents. Further, he’s led major projects and negotiated over $1 billion in commercial agreements and dispute resolutions in 15 countries. Truly, he is a powerhouse executive.

New Chief Financial Officer John Poss comments, “I am very happy to join GrowBLOX. As a Cancer survivor, I am a strong believer in the value of medical marijuana in many cases and to treat many diseases. I am excited to be a part of this revolution, which has been developing, slowly, throughout my lifetime.”

Chief Executive Officer Craig Ellins summed it up by saying, “John’s experience, in business and in life, speaks for itself.”

About GrowBLOX Sciences, Inc.

GrowBLOX Sciences, Inc. (GBLX) is a biopharmaceutical research and development company focused on creating safe, standardized, pharmaceutical-grade, cannabinoid therapies that target a variety of medical conditions. The Company has leading technology and cannabis industry processes, with a “big” data-driven clinical research and development loop to bring relief to patients in communities across the country. Through our GBS PR subsidiary, we are developing and globally distributing our GrowBLOX(TM) suite of cultivation and growing chambers. To learn more about GrowBLOX Sciences, Inc., go to: https://growblox.com.

Forward-Looking Statements

This press release may contain statements relating to future results or events, which are forward-looking statements. Words such as “expects”, “intends”, “plans”, “may”, “could”, “should”, “anticipates”, “likely”, “believes” and words of similar import may identify forward-looking statements. These statements are not historical facts, but instead represent only the Company’s belief regarding future events, many of which, by their nature, are inherently uncertain and outside of the Company’s control. It is possible that the Company’s actual results and financial condition may differ, possibly materially, from the anticipated results and financial condition indicated in these forward-looking statements. Further, information concerning the Company and its business, including factors that potentially could materially affect the Company’s business and financial and other results, are contained in the Company’s filings with the Securities and Exchange Commission, available at www.sec.gov. All forward-looking statements included in this press release are made only as of the date of this press release, and we do not undertake any obligation to publicly update or correct any forward-looking statements to reflect events or circumstances that subsequently occur or of which we hereafter become aware.

Note: Although the Company’s research and development activities are not illegal, the production and sale of cannabis products violate federal laws as presently constituted.

GrowBLOX is a registered trademark of GrowBLOX Sciences, Inc.

Contact Information

Corporate:
GrowBLOX Sciences, Inc.,
6450 Cameron Street, Suite 110A, Las Vegas, NV 89118
866-721-0297
Craig Ellins, CEO
Andrea Small Howard, Chief Science Officer
craig@gbsciences.com
andrea@gbsciences.com
https://growblox.com

Investors:
Hayden IR
hart@haydenir.com
917-658-7878

SOURCE: GrowBLOX Sciences, Inc